Case Report: Long-term disease-free survival in an advanced hepatocellular carcinoma patient: an exceptional response to PD-1 inhibitor therapy [PDF]
Frontiers in ImmunologyIntroductionHepatocellular carcinoma (HCC) is a leading cause of cancer-related death, with most patients diagnosed at advanced stages, often precluding surgical resection.
Qinliang Fang +14 more
doaj +2 more sources
Analysis of different prognoses in two hepatocellular carcinoma patients with pathological complete response after conversion therapy: a case report [PDF]
Journal of Medical Case ReportsBackground Hepatocellular carcinoma is a common lethal malignancy, with most patients diagnosed at an advanced stage, precluding surgical resection. Conversion therapy combining locoregional and systemic treatments has emerged as an effective approach to
Qinliang Fang +5 more
doaj +2 more sources
Hsa-miR-423-5p selectively loaded in hypoxic exosomes reduces the sensitivity of normoxic hepatocellular carcinoma to sorafenib via autophagy [PDF]
Cancer Cell InternationalBackground For patients with advanced hepatocellular carcinoma, sorafenib is considered a highly effective targeted molecular drug; however, sorafenib resistance limits its therapeutic efficacy.
Bian Shu +9 more
doaj +2 more sources
Journal of Translational Medicine, 2023 Background Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide because of rapid progression and high incidence of metastasis or recurrence.
Chuanzheng Wang +7 more
doaj +1 more source
Resveratrol protects against chronic alcohol-induced liver disease in a rat model
STEMedicine, 2022 Hepatic ethanol metabolism participates in the pathogenesis of alcoholic liver disease (ALD). We aimed to evaluate the protecting effects and underlying mechanisms of Resveratrol against ALD.
Hanzhang Zhu +3 more
doaj +1 more source
AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
Hepatology, 2023 for End-Stage Liver Disease;
A. Singal +15 more
semanticscholar +1 more source
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
New England Journal of Medicine, 2020 BACKGROUND The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma. METHODS In a global, open-label, phase 3 trial, patients with
R. Finn +20 more
semanticscholar +1 more source
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.
NEJM Evidence, 2022 Tremelimumab/Durvalumab for Hepatocellular CarcinomaThis trial examined overall survival (OS) with tremelimumab plus durvalumab, durvalumab alone, or sorafenib in untreated patients with hepatocellular cancer who were not candidates for locoregional ...
G. Abou-Alfa +30 more
semanticscholar +1 more source
Heat shock protein HSPA13 promotes hepatocellular carcinoma progression by stabilizing TANK
Cell Death Discovery, 2023 HSPA13, an important member of the heat shock protein family, plays an essential role in the oncogenesis of many organs, but the mechanism and function in hepatocellular carcinoma (HCC) is still unclear.
Xuesong Cen +9 more
doaj +1 more source
Hepatology Research, 2023 The fifth version of the Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence‐based medicine and partly to the Grading of Recommendations Assessment ...
K. Hasegawa +26 more
semanticscholar +1 more source